The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

HER2 Targeting Therapies Market by Target Disease Indication (Breast Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, and Ovarian Cancer), Type of Molecule (Biologic and Small Molecule), Type of Therapy (Monotherapy, Combination Therapy and Both) and Route of Administration (Intravenous and Oral), Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    July 2021

  • Pages
    250

  • View Count
    1408

Example Insights

HER2-Targeting-Therapeutics-Market-Context HER2-Targeting-Therapeutics-Market-Pipeline HER2-Targeting-Therapeutics-Market-Distribution-by-Clinical-Trial-Phase
HER2-Targeting-Therapeutics-Market-Geographical-Distribution HER2-Targeting-Therapeutics-Market-Grant-Analysis HER2-Targeting-Therapeutics-Market-List-of-Companion-Diagnostics
HER2-Targeting-Therapeutics-Market-Partnerships-and-Collaborations HER2-Targeting-Therapeutics-Market-Likely-Growth-Scenarios HER2-Targeting-Therapeutics-Market-Opportunity

 

Overview

Human epidermal growth factor receptor 2 (HER2), a member of human epidermal growth factor receptor family, plays an important role in the development and progression of various types of cancers, especially breast cancer. Over time, it has been found to be an important target for the drug therapies intended for treating various types of breast cancer. HER2 targeting therapies have shown to be a promising treatment option, capable of preventing tumor cells from evading immune surveillance. In 1998, the FDA approved the first HER2 targeting monoclonal antibody, called Herceptin® (trastuzumab) for the treatment of metastatic breast cancer. Later, in 2006, the drug got approved for HER2 positive early breast cancer. Following its success in treating breast cancer, significant efforts were made to evaluate its potential in other conditions involving HER2 alterations, such as overexpression, amplifications and other mutations. Eventually in 2010, the drug got FDA approval for HER2 positive metastatic stomach cancer as well.  In addition to Herceptin, more than five drugs have been approved and about 70 candidates are under development for breast cancer, HER2-positive biliary tract, colorectal, non-small-cell lung and gastric cancers. Further, combinatorial studies of HER2 targeting therapeutics along with immune checkpoint inhibitors have also shown positive results across various disease indications.

Presently, several companies, including well-established players and new entrants, are actively engaged in developing the HER2 targeting therapies for a wide variety of disease indications. Innovation in this field is mostly focused on improving the therapeutic efficacy and safety, and overall survival rate. The research activity has gained significant attention from private and public investors, which have extended their financial support to capable developer companies. The market has also witnessed substantial partnership activity over the last few years. Driven by the success of the currently available drugs / therapy products and the encouraging clinical trial results, the market is poised to witness healthy growth as multiple late stage drugs get approved and marketed over the next decade.

Scope of the Report

The “HER2 Targeting Therapies Market, 2021-2031” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed review of the current market landscape of HER2 targeting therapies, including analyses based on several parameters, such as current status of development (marketed, clinical, pre-clinical and discovery), phase of development (phase III, phase II/III, phase II, phase I/II and phase I) of lead candidates, type of molecule (biologic and small molecule), type of biologic (antibody drug conjugates, bispecific antibodies, CAR-T cell therapies, monoclonal antibodies, vaccines and others), type of therapy (monotherapy, combination therapy and both), target disease indication, target therapeutic area and route of administration (intravenous, intradermal, oral and others).
  • A detailed analysis of completed, ongoing and planned clinical trials of HER2 targeting therapies, highlighting prevalent trends across various relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, target therapeutic area, popular indications and regional distribution of trials.
  • Elaborate profiles of the companies developing HER2 targeting therapies. Each profile features a brief overview of the company, details on its product portfolio, and recent developments and an informed future outlook.
  • An in-depth analysis of grants awarded to various research institutes for projects related to HER2 targeting therapies, in the period between 2018 and 2021 (till March), on the basis of several parameters, such as year of award, amount awarded, funding institute center, support period, type of grant application, purpose of grant award, activity code, focus area, responsible study section, popular NIH departments, prominent program officers and type of recipient organizations. In addition, it highlights the geographical distribution of recipient organizations.
  • An analysis of the partnerships established between various stakeholders in this domain, during the period 2017-2021, covering R&D agreements, licensing agreements (specific to affiliated technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, manufacturing agreements, mergers and acquisitions, manufacturing agreements and other relevant types of deals. 
  • A case study on HER2 targeting biosimilars, including a review of the current market landscape of HER2 targeting biosimilar molecules, and a detailed analysis based on several parameters, such as parent drug, phase of development and target disease indications. The chapter also provides information on the companies involved in the development of these HER2 targeting biosimilars.
  • A case study on companion diagnostic tests developed / being developed for various HER2 targeting drug candidates, including a detailed analysis based on commercial availability, assay technique used, corresponding drug candidate and target disease indication. In addition, the chapter provides information on the companies engaged in the development of companion diagnostics for HER2 targeting drug candidates.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for HER2 targeting therapies, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption rates and likely selling price of HER2 targeting therapies, we have provided informed estimates on the evolution of the market for the period 2021-2031. The report also features the likely distribution of the current and forecasted opportunity across [A] different target indications (breast cancer, gastric cancer head and neck cancer and lung cancer) [B] type of molecule (small molecule and biologic), [C] type of therapy (monotherapy, combination therapy and both), [D] route of administration (intravenous and oral) and [E] key geographical regions (US, Europe, Asia-Pacific, Middle East and North Africa and Latin America). To account for the future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in the report are in USD, unless otherwise specified.

Key Questions Answered

  • What are the key therapeutic indications for which HER2 targeting therapies have been / are being developed?
  • Who are the leading industry and non-industry players in this domain?
  • Which geographies are the most active in conducting clinical trials on HER2 targeting therapies?
  • Which are the leading funding organizations for providing grants in this domain?
  • Which partnership models are commonly adopted by industry stakeholders? 
  • Which players are involved in developing companion diagnostics for HER2 targeting therapies?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the HER2 targeting therapies market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to various aspects of cancer immunotherapy. The chapter lays emphasis on the role of targeting therapies in cancer treatment, including details on the HER2 mutations, mechanism of action of HER2 targeting therapies and the type of molecules that are developed / being developed. Further, it includes a discussion on the various challenges associated with the use of HER2 targeting therapies and highlights certain future perspectives.

Chapter 4 provides an overview of more than 200 molecules that are currently under development for the treatment of various cancer indications, along with a detailed analysis of these molecules, based on phase of development (marketed, clinical, preclinical and discovery stage) of lead candidates, type of molecule (biologic and small molecule), type of biologic (antibody drug conjugates, bispecific antibodies, CAR-T cell therapies, monoclonal antibodies, vaccines and others), type of therapy (monotherapy, combination therapy and both), target disease indication(s),  therapeutic area(s) and route of administration (intradermal, intravenous, oral, and others). In addition, the chapter provides information on drug developer(s), highlighting their year of establishment, company size and geographical location of headquarters.

Chapter 5 includes detailed profiles of the key players (shortlisted based on number of pipeline products) engaged in the development of HER2 targeting therapies. Each profile includes a brief overview of the company, details on its product portfolio, and recent developments and an informed future outlook.

Chapter 6 provides a detailed analysis of more than 1,500 completed, ongoing and planned clinical studies of HER2 targeting therapies, based on the parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors (in terms of number of trials conducted), study focus, target indication(s), focus areas, target therapeutic area(s), enrolled patient population and regional distribution of trials.

Chapter 7 provides an analysis of more than 1,300 grants awarded to research institutes engaged in the projects related to HER2 targeting therapies, in the period between 2018 and 2021 (till March) based on important parameters, such as year of grant award, amount awarded, funding institute center, support period, type of grant application, purpose of grant award, grant mechanism, responsible study section, focus area, prominent program officers, and recipient organizations.

Chapter 8 features a detailed analysis of the various partnerships and collaborations that have been established amongst the stakeholders in this domain, since 2017. It includes a brief description of various types of partnership models (namely acquisitions, licensing agreements, product development and commercialization agreements, research agreements, and other agreements) adopted by stakeholders. It also includes analysis of the key companies that have established maximum number of partnerships, highlighting most popular type of molecule, and target disease indications.

Chapter 9 includes an insightful market forecast analysis, presenting the likely growth of HER2 targeting therapies market till the year 2031. In addition, we have provided inputs on the likely distribution of the market opportunity based on different target indications (breast cancer, gastric cancer, head and neck cancer and lung cancer), type of molecule (small molecule and biologic), type of therapy (monotherapy, combination therapy and both), route of administration (intravenous and oral) and key geographical regions (US, Europe, Asia-Pacific, Middle East and North Africa and Latin America). To account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

Chapter 10 presents a case study on HER2 targeting biosimilars, highlighting market landscape of various biosimilars molecules that are developed / being developed. These molecules are further analyzed on the basis of several parameters, such as parent drug, phase of development and target disease indications. This chapter also provide insights on developer landscape, including information on year of establishment and geographical location of headquarters of the companies.

Chapter 11 features a case study on companion diagnostic tests for that are developed / being developed corresponding to various HER2 targeting drug candidates, and their analysis on the basis of their commercial availability, assay technique used, corresponding drug candidate and target disease indication. This chapter also provide insights on developer landscape, including information on year of establishment and geographical location of headquarters of the companies.

Chapter 12 is a summary of the overall report, which presents the insights on the contemporary market trends and the likely evolution of the HER2 targeting therapies market.

Chapter 13 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Cancer Immunotherapy
3.3. Fundamentals of Cancer Immunotherapy
3.4. HER2 Mutations
3.5. Overview of HER2 Targeting Therapies
3.5.1 Biologics Targeting HER2
3.5.1.1 Types of Products
3.5.2 Small Molecules Targeting HER2
3.5.2.1 Types of Products
3.6. Existing Challenges and Future Perspectives

4. CURRENT MARKET LANDSCAPE: MARKETED PRODUCTS AND DEVELOPMENT PIPELINE
4.1. Chapter Overview
4.2. HER2 Targeting Therapies: Marketed Products and Development Pipeline

4.3. HER2 Targeting Therapies: Pipeline Analysis
4.3.1. Analysis by Current Status
4.3.2. Analysis by Phase of Development
4.3.3. Analysis by Type of Molecule
4.3.4. Analysis by Type of Biologic
4.3.5. Analysis by Type of Therapy
4.3.6. Analysis by Target Disease Indication
4.3.7. Analysis by Route of Administration
4.3.8. Analysis by Phase of Development and Type of Molecule
4.3.9. Analysis by Phase of Development and Route of Administration

4.4. HER2 Targeting Therapies: Developer Landscape
4.4.1. Analysis by Type of Developer
4.4.2. Analysis by Year of Establishment
4.4.3. Analysis by Company Size
4.4.4. Analysis by Geographical Location
4.4.5. Analysis by Company Size and Geographical Location
4.4.6. Leading Industry Players: Analysis by Number of Therapies
4.4.7. Leading Non-Industry Players: Analysis by Number of Therapies

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. AstraZeneca
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. HER2 Targeting Therapies Portfolio
5.2.4. Recent Developments and Future Outlook

5.3. Boehringer Ingelheim
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. HER2 Targeting Therapies Portfolio
5.3.4. Recent Developments and Future Outlook

5.4. GlaxoSmithKline
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. HER2 Targeting Therapies Portfolio
5.4.4. Recent Developments and Future Outlook

5.5. MacroGenics
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. HER2 Targeting Therapies Portfolio
5.5.4. Recent Developments and Future Outlook

5.6. Pfizer
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. HER2 Targeting Therapies Portfolio
5.6.4. Recent Developments and Future Outlook

5.7. Puma Biotechnology
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. HER2 Targeting Therapies Portfolio
5.7.4. Recent Developments and Future Outlook

5.8. Roche
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. HER2 Targeting Therapies Portfolio
5.8.4. Recent Developments and Future Outlook

5.9. Seagen (previously Seattle Genetics)
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. HER2 Targeting Therapies Portfolio
5.9.4. Recent Developments and Future Outlook

5.10. Triumvira Immunologics
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. HER2 Targeting Therapies Portfolio
5.10.4. Recent Developments and Future Outlook

5.11. Zymeworks
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. HER2 Targeting Therapies Portfolio
5.11.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS 
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. HER2 Targeting Therapies: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Phase and Enrolled Patient Population
6.3.3. Analysis by Trial Registration Year and Enrolled Patient Population
6.3.4. Analysis by Study Design
6.3.5. Analysis by Sponsor / Collaborator
6.3.6. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.7. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.3.8. Analysis by Trial Focus
6.3.9. Analysis by Target Disease Indication
6.3.10. Analysis by Target Therapeutic Area 
6.3.11. Geographical Analysis by Number of Registered Trials 
6.3.12. Geographical Analysis by Enrolled Patient Population 

7. ACADEMIC GRANTS ANALYSIS
7.1. Chapter Overview
7.2. ` Scope and Methodology

7.3. HER2 Targeting Therapies: Analysis of Awarded Grants
7.3.1. Analysis by Year of Grant Award
7.3.2. Analysis by Amount Awarded
7.3.3. Analysis by Funding Institute Center
7.3.4. Analysis by Support Period
7.3.5. Analysis by Funding Institute Center and Support Period
7.3.6. Analysis by Type of Grant Application
7.3.7. Analysis by Purpose of Grant Award
7.3.8. Analysis by Activity Code
7.3.9. Word Cloud Analysis: Emerging Focus Areas
7.3.10. Analysis by Study Section Involved
7.3.11. Popular NIH Departments: Analysis by Number of Grants Awarded
7.3.12. Prominent Program Officers: Analysis by Number of Grants Awarded
7.3.13. Analysis by Type of Recipient Organization
7.3.14. Popular Recipient Organizations: Analysis by Number of Grants Awarded
7.3.15. Regional Distribution of Recipient Organizations

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models

8.3. HER2 Targeting Therapies: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partner
8.3.4. Analysis by Type of Partnership and Type of Partner
8.3.5. Most Active Players: Analysis by Number of Partnerships

8.4. Regional Analysis
8.4.1. Intercontinental and Intracontinental Agreements

9. MARKET SIZING AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global HER2 Targeting Therapies Market, 2021-2031
9.4. HER2 Targeting Therapies: Individual Product Sales Forecasts 
9.4.1. BAT8001 (Bio-Thera Solutions)
9.4.1.1. Target Patient Population
9.4.1.2. Sales Forecast

9.4.2. ENHERTU® (AstraZeneca)
9.4.2.1. Target Patient Population
9.4.2.2. Sales Forecast

9.4.3. Gilotrif® (Boehringer Ingelheim)
9.4.3.1. Target Patient Population
9.4.3.2. Sales Forecast

9.4.4. KADCYLA™ (Roche)
9.4.4.1. Target Patient Population
9.4.4.2. Sales Forecast

9.4.5. MARGENZA™ (MacroGenics)
9.4.5.1. Target Patient Population
9.4.5.2. Sales Forecast

9.4.6. RC48 (RemeGen)
9.4.6.1. Target Patient Population
9.4.6.2. Sales Forecast

9.4.7. Nerlynx™ (Puma Biotechnology)
9.4.7.1. Target Patient Population
9.4.7.2. Sales Forecast

9.4.8. Perjeta® (Genentech, a Roche’s company)
9.4.8.1. Target Patient Population
9.4.8.2. Sales Forecast

9.4.9. SYD985 (Byondis)
9.4.9.1. Target Patient Population
9.4.9.2. Sales Forecast

9.4.10. MOBOCERTINIB (Takeda)
9.4.10.1. Target Patient Population
9.4.10.2. Sales Forecast

9.4.11. Tukysa® (Seagen)
9.4.11.1. Target Patient Population
9.4.11.2. Sales Forecast

9.4.12. Tyverb® (Roche)
9.4.12.1. Target Patient Population
9.4.12.2. Sales Forecast

9.4.13. Vizimpro® (Pfizer)
9.4.13.1. Target Patient Population
9.4.13.2. Sales Forecast

9.5. Global HER2 Targeting Therapies Market, 2021-2031: Distribution by Geography
9.5.1. HER2 Targeting Therapies Market in the North America, 2021-2031
9.5.2. HER2 Targeting Therapies Market in Europe, 2021-2031
9.5.3. HER2 Targeting Therapies Market in Asia Pacific, 2021-2031
9.5.4. HER2 Targeting Therapies Market in Middle East and North Africa, 2021-2031
9.5.5. HER2 Targeting Therapies Market in Latin America, 2021-2031

9.6. Global HER2 Targeting Therapies Market: Distribution by Target Disease Indication
9.6.1. Global HER2 Targeting Therapies Market for Breast Cancer, 2021-2031
9.6.2. Global HER2 Targeting Therapies Market for Gastric Cancer, 2021-2031
9.6.3. Global HER2 Targeting Therapies Market for Head and Neck Cancer, 2021-2031
9.6.4. Global HER2 Targeting Therapies Market for Lung Cancer, 2021-2031
 
9.7. Global HER2 Targeting Therapies Market: Distribution by Type of Molecule
9.7.1. Global HER2 Targeting Therapies Market for Biologics, 2021-2031
9.7.2. Global HER2 Targeting Therapies Market for Small Molecules, 2021-2031

9.8. Global HER2 Targeting Therapies Market: Distribution by Type of Therapy
9.8.1. Global HER2 Targeting Therapies Market for Monotherapy, 2021-2031
9.8.2. Global HER2 Targeting Therapies Market for Combination Therapy, 2021-2031
9.8.3. Global HER2 Targeting Therapies Market for Both Therapies, 2021-2031

9.9. Global HER2 Targeting Therapies Market: Distribution by Route of Administration
9.9.1. Global HER2 Targeting Therapies Market for Intravenous Therapies, 2021-2031
9.9.2. Global HER2 Targeting Therapies Market for Oral Therapies, 2021-2030

10. CASE STUDY: HER2 TARGETING BIOSIMILARS
10.1. Chapter Overview
10.2. HER2 Targeting Biosimilars: Marketed Products and Development Pipeline
10.3. HER2 Targeting Biosimilars: Pipeline Analysis
10.3.1. Analysis by Parent Drug
10.3.2. Analysis by Phase of Development of Biosimilar
10.3.3. Analysis by Target Disease Indication

10.4. HER2 Targeting Biosimilars: Developer Landscape
10.4.1. Analysis by Year of Establishment
10.4.2. Analysis by Geographical Location
10.4.3. Analysis by Company Size and Geographical Location

11. CASE STUDY: COMPANION DIAGNOSTICS FOR HER2 TARGETING THERAPIES
11.1. Chapter Overview
11.2. Companion Diagnostics for HER2 Targeting Therapies
11.2.1. Analysis by Commercial Availability of the Test
11.2.2. Analysis by Assay Technique Used
11.2.3. Analysis by Corresponding Drug Candidate
11.2.4. Analysis by Target Disease Indication

11.3. Companion Diagnostics for HER2 Targeting Therapies: Developer Overview
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3. Analysis by Geographical Location

12. CONCLUDING REMARKS

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 HER2 Signaling Pathway
Figure 4.1 HER2 Targeting Therapies: Distribution by Current Status
Figure 4.2 HER2 Targeting Therapies: Distribution by Phase of Development
Figure 4.3 HER2 Targeting Therapies: Distribution by Type of Molecule
Figure 4.4 HER2 Targeting Therapies: Distribution by Type of Biologic
Figure 4.5 HER2 Targeting Therapies: Distribution by Type of Therapy
Figure 4.6 HER2 Targeting Therapies: Distribution by Target Disease Indication
Figure 4.7 HER2 Targeting Therapies: Distribution by Route of Administration
Figure 4.8 HER2 Targeting Therapies Developers: Distribution by Type of Developer
Figure 4.9 HER2 Targeting Therapies Developers: Distribution by Year of Establishment
Figure 4.10 HER2 Targeting Therapies Developers: Distribution by Company Size
Figure 4.11 HER2 Targeting Therapies Developers: Distribution by Geographical Location
Figure 4.12 HER2 Targeting Therapies Developers: Distribution by Company Size and Geographical Location
Figure 4.13 Leading Industry Players: Distribution by Number of Pipeline Candidates
Figure 4.14 Leading Non-Industry Players: Distribution by Number of Pipeline Candidates
Figure 6.1 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year 2000-2021
Figure 6.2 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 6.5 Clinical Trial Analysis: Distribution by Study Design
Figure 6.6 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.7 Leading Players: Distribution by Number of Registered Trials
Figure 6.8 Word Cloud: Key Focus Areas
Figure 6.9 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 6.10 Clinical Trial Analysis: Distribution by Trial Registration Year and Target Gene
Figure 6.11 Popular Indications: Distribution by Number of Registered Trials
Figure 6.12 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 6.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.1 Grant Analysis: Cumulative Trend by Year of Grant Award, 2018-2021
Figure 7.2 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), 2018-2021
Figure 7.3 Grant Analysis: Distribution by Funding Institute Center
Figure 7.4 Grant Analysis: Distribution by Support Period
Figure 7.5 Grant Analysis: Distribution by Administering Institute Center and Support Period
Figure 7.6 Grant Analysis: Distribution by Type of Grant Application
Figure 7.7 Grant Analysis: Distribution by Purpose of Grant Award
Figure 7.8 Grant Analysis: Distribution by Activity Code
Figure 7.9 Word Cloud Analysis: Emerging Focus Areas
Figure 7.10 Grant Analysis: Distribution by Study Section Involved
Figure 7.11 Grant Analysis: Distribution by Type of Recipient Organization
Figure 7.12 Popular NIH Departments: Distribution by Number of Grants
Figure 7.13 Prominent Program Officers: Distribution by Number of Grants Awarded
Figure 7.14 Prominent Program Officers: Distribution by Number of Grants
Figure 7.15 Popular Recipient Organizations: Distribution by Number of Grants Awarded
Figure 7.16 Grant Analysis: Geographical Distribution of Recipient Organizations
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2021
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partnership and Year of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Molecule
Figure 8.6 Most Active Players: Distribution by Number of Partnerships
Figure 8.7 Partnerships and Collaborations: Regional Distribution
Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Global HER2 Targeting Therapies Market, 2021-2031 (USD Million)
Figure 9.2 BAT8001 (Bio-Thera Solutions): Sales Forecast, till 2031 (USD Million)
Figure 9.3 ENHERTU® (AstraZeneca): Sales Forecast, till 2031 (USD Million)
Figure 9.4 Gilotrif® (Boehringer Ingelheim): Sales Forecast, till 2031 (USD Million)
Figure 9.5 KADCYLA™ (Roche): Sales Forecast, till 2031 (USD Million)
Figure 9.6 Margenza™ (MacroGenics): Sales Forecast, till 2031 (USD Million)
Figure 9.7 RC48 (RemeGen): Sales Forecast, till 2031 (USD Million)
Figure 9.8 Nerlynx™ (Puma Biotechnology): Sales Forecast, till 2031 (USD Million)
Figure 9.9 Perjeta® (Genentech, a Roche’s company): Sales Forecast, till 2031 (USD Million)
Figure 9.10 SYD985 (Byondis): Sales Forecast, till 2031 (USD Million)
Figure 9.11 MOBOCERTINIB (Takeda): Sales Forecast, till 2031 (USD Million)
Figure 9.12 Tukysa® (Seagen): Sales Forecast, till 2031 (USD Million)
Figure 9.13 Tyverb® (Roche): Sales Forecast, till 2031 (USD Million)
Figure 9.14 Vizimpro® (Pfizer): Sales Forecast, till 2031 (USD Million)
Figure 9.15 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Geography (USD Million)
Figure 9.16 HER2 Targeting Therapies Market in North America, 2021-2031 (USD Million)
Figure 9.17 HER2 Targeting Therapies Market in Europe, 2021-2031 (USD Million)
Figure 9.18 HER2 Targeting Therapies Market in Asia Pacific, 2021-2031 (USD Million)
Figure 9.19 HER2 Targeting Therapies Market in Middle East and North Africa, 2021-2031 (USD Million)
Figure 9.20 HER2 Targeting Therapies Market in Latin America, 2021-2031 (USD Million)
Figure 9.21 Global HER2 Targeting Therapies Market 2021 and 2031: Distribution by Target Disease Indication (USD Million)
Figure 9.22 HER2 Targeting Therapies Market for Breast Cancer, 2021-2031 (USD Million)
Figure 9.23 HER2 Targeting Therapies Market for Gastric Cancer, 2021-2031 (USD Million)
Figure 9.24 HER2 Targeting Therapies Market for Head and Neck Cancer, 2021-2031 (USD Million)
Figure 9.25 HER2 Targeting Therapies Market for Lung Cancer, 2021-2031 (USD Million)
Figure 9.26 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Type of Molecule (USD Million)
Figure 9.27 HER2 Targeting Therapies Market for Biologics, 2021-2031 (USD Million)
Figure 9.28 HER2 Targeting Therapies Market for Small Molecules, 2021-2031 (USD Million)
Figure 9.29 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Type of Therapy (USD Million)
Figure 9.30 HER2 Targeting Therapies Market for Monotherapy, 2021-2031 (USD Million)
Figure 9.31 HER2 Targeting Therapies Market for Combination Therapy, 2021-2031 (USD Million)
Figure 9.32 HER2 Targeting Therapies Market for Both, 2021-2031 (USD Million)
Figure 9.33 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Route of Administration (USD Million)
Figure 9.34 HER2 Targeting Therapies Market for Intravenous Therapies, 2021-2031 (USD Million)
Figure 9.35 HER2 Targeting Therapies Market for Oral Therapies, 2021-2031 (USD Million)
Figure 10.1 HER2 Targeting Biosimilars: Distribution by Parent Drug
Figure 10.2 HER2 Targeting Biosimilars: Distribution by Phase of Development of Biosimilar
Figure 10.3 HER2 Targeting Biosimilars: Distribution by Target Disease Indication
Figure 10.4 HER2 Targeting Biosimilar Developers: Distribution by Year of Establishment
Figure 10.5 HER2 Targeting Biosimilar Developers: Distribution by Geographical Location
Figure 10.6 HER2 Targeting Biosimilar Developers: Distribution by Company Size and Geographical Location
Figure 11.1 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Commercial Availability of the Test
Figure 11.2 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Assay Technique Used
Figure 11.3 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Corresponding Drug Candidate
Figure 11.4 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Target Disease Indication
Figure 11.5 Companion Diagnostics for HER2 Targeting Therapies: Distribution of Developers by Year of Establishment
Figure 11.6 Companion Diagnostics for HER2 Targeting Therapies: Distribution of Developers by Company Size
Figure 11.7 Companion Diagnostics for HER2 Targeting Therapies: Distribution of Developers by Geographical Location
Figure 12.1 Concluding Remarks: Overall Market Landscape
Figure 12.2 Concluding Remarks: Clinical Trial Analysis
Figure 12.3 Concluding Remarks: Grant Analysis
Figure 12.4 Concluding Remarks: Partnerships and Collaborations
Figure 12.5 Concluding Remarks: Market Forecast

List Of Tables

Table 4.1 HER2 Targeting Therapies: List of Therapies
Table 4.2 HER2 Targeting Therapies: List of Developers
Table 5.1 HER2 Targeting Therapies List of Companies Profiled
Table 5.2 AstraZeneca: Company Snapshot
Table 5.3 Drug Profile: ENHERTU®
Table 5.4 Drug Profile: AZD8931
Table 5.5 Boehringer Ingelheim: Company Snapshot
Table 5.6 Drug Profile: Gilotrif®
Table 5.7 GlaxoSmithKline: Company Snapshot
Table 5.8 Drug Profile: Tyverb®
Table 5.9 Drug Profile: SB719125
Table 5.10 MacroGenics: Company Snapshot
Table 5.11 Drug Profile: MARGENZA™
Table 5.12 Pfizer: Company Snapshot
Table 5.13 Drug Profile: Vizimpro®
Table 5.14 Drug Profile: CP-724714
Table 5.15 Drug Profile: PF-06804103
Table 5.16 Puma Biotechnology: Company Snapshot
Table 5.17 Drug Profile: Nerlynx™
Table 5.18 Roche: Company Snapshot
Table 5.19 Drug Profile: PERJETA®
Table 5.20 Drug Profile: Kadcyla™
Table 5.21 Drug Profile: RG6194
Table 5.22 Drug Profile: BTRC4017A
Table 5.23 Drug Profile: RG6148
Table 5.24 Seagen: Company Snapshot
Table 5.25 Drug Profile: Tukysa®
Table 5.26 Triumvira Immunologics: Company Snapshot
Table 5.27 Drug Profile: TAC01
Table 5.28 Drug Profile: TAC02
Table 5.29 ZymeWorks: Company Snapshot
Table 5.30 Drug Profile: ZW25
Table 5.31 Drug Profile: ZW49

Table 8.1 HER2 Targeting Therapies: List of Partnerships and Collaborations
Table 9.1 HER2 Targeting Therapies: List of Forecasted Therapies
Table 10.1 HER2 Targeting Biosimilars: List of Therapies
Table 10.2 HER2 Targeting Biosimilars: List of Developers
Table 11.1 Companion Diagnostics for HER2 Targeting Therapies: List of Products
Table 11.2 Companion Diagnostics for HER2 Targeting Therapies: List of Developers
Table 13.1 HER2 Targeting Therapies: Distribution by Current Status
Table 13.2 HER2 Targeting Therapies: Distribution by Phase of Development
Table 13.3 HER2 Targeting Therapies: Distribution by Type of Molecule
Table 13.4 HER2 Targeting Therapies: Distribution by Type of Biologic
Table 13.5 HER2 Targeting Therapies: Distribution by Type of Therapy
Table 13.6 HER2 Targeting Therapies: Distribution by Target Disease Indication
Table 13.7 HER2 Targeting Therapies: Distribution by Route of Administration
Table 13.8 HER2 Targeting Therapies Developers: Distribution by Type of Developer
Table 13.9 HER2 Targeting Therapies Developers: Distribution by Year of Establishment
Table 13.10 HER2 Targeting Therapies Developers: Distribution by Company Size
Table 13.11 HER2 Targeting Therapies Developers: Distribution by Geographical Location
Table 13.12 HER2 Targeting Therapies Developers: Distribution by Company Size and Geographical Location
Table 13.13 Leading Industry Players: Distribution by Number of Pipeline Candidates
Table 13.14 Leading Non-Industry Players: Distribution by Number of Pipeline Candidates
Table 13.15 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year 2000-2021
Table 13.16 Clinical Trial Analysis: Distribution by Trial Phase
Table 13.17 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 13.18 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 13.19 Clinical Trial Analysis: Distribution by Study Design
Table 13.20 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 13.21 Leading Players: Distribution by Number of Registered Trials
Table 13.22 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table 13.23 Clinical Trial Analysis: Distribution by Trial Registration Year and Target Gene
Table 13.24 Popular Indications: Distribution by Number of Registered Trials
Table 13.25 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table 13.26 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 13.27 Grant Analysis: Cumulative Trend by Year of Grant Award, 2018-2021
Table 13.28 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), 2018-2021
Table 13.29 Grant Analysis: Distribution by Funding Institute Center
Table 13.30 Grant Analysis: Distribution by Support Period
Table 13.31 Grant Analysis: Distribution by Administering Institute Center and Support Period
Table 13.32 Grant Analysis: Distribution by Type of Grant Application
Table 13.33 Grant Analysis: Distribution by Purpose of Grant Award
Table 13.34 Grant Analysis: Distribution by Activity Code
Table 13.35 Grant Analysis: Distribution by Study Section Involved
Table 13.36 Grant Analysis: Distribution by Type of Recipient Organization
Table 13.37 Popular NIH Departments: Distribution by Number of Grants
Table 13.38 Prominent Program Officers: Distribution by Number of Grants Awarded
Table 13.39 Prominent Program Officers: Distribution by Number of Grants
Table 13.40 Popular Recipient Organizations: Distribution by Number of Grants Awarded
Table 13.41 Grant Analysis: Geographical Distribution of Recipient Organizations
Table 13.42 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2021
Table 13.43 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.44 Partnerships and Collaborations: Distribution by Type of Partnership and Year of Partnership
Table 13.45 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 13.46 Partnerships and Collaborations: Distribution by Type of Molecule
Table 13.47 Most Active Players: Distribution by Number of Partnerships
Table 13.48 Partnerships and Collaborations: Regional Distribution
Table 13.49 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 13.50 Global HER2 Targeting Therapies Market, 2021-2031 (USD Million)
Table 13.51 BAT8001 (Bio-Thera Solutions): Sales Forecast, till 2031 (USD Million)
Table 13.52 ENHERTU® (AstraZeneca): Sales Forecast, till 2031 (USD Million)
Table 13.53 Gilotrif® (Boehringer Ingelheim): Sales Forecast, till 2031 (USD Million)
Table 13.54 KADCYLA™ (Roche): Sales Forecast, till 2031 (USD Million)
Table 13.55 Margenza™ (MacroGenics): Sales Forecast, till 2031 (USD Million)
Table 13.56 RC48 (RemeGen): Sales Forecast, till 2031 (USD Million)
Table 13.57 Nerlynx™ (Puma Biotechnology): Sales Forecast, till 2031 (USD Million)
Table 13.58 Perjeta® (Genentech, a Roche’s company): Sales Forecast, till 2031 (USD Million)
Table 13.59 SYD985 (Byondis): Sales Forecast, till 2031 (USD Million)
Table 13.60 MOBOCERTINIB (Takeda): Sales Forecast, till 2031 (USD Million)
Table 13.61 Tukysa® (Seagen): Sales Forecast, till 2031 (USD Million)
Table 13.62 Tyverb® (Roche): Sales Forecast, till 2031 (USD Million)
Table 13.63 Vizimpro® (Pfizer): Sales Forecast, till 2031 (USD Million)
Table 13.64 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Geography (USD Million)
Table 13.65 HER2 Targeting Therapies Market in North America, 2021-2031 (USD Million)
Table 13.66 HER2 Targeting Therapies Market in Europe, 2021-2031 (USD Million)
Table 13.67 HER2 Targeting Therapies Market in Asia Pacific, 2021-2031 (USD Million)
Table 13.68 HER2 Targeting Therapies Market in Middle East and North Africa, 2021-2031 (USD Million)
Table 13.69 HER2 Targeting Therapies Market in Latin America, 2021-2031 (USD Million)
Table 13.70 Global HER2 Targeting Therapies Market 2021 and 2031: Distribution by Target Disease Indication (USD Million)
Table 13.71 HER2 Targeting Therapies Market for Breast Cancer, 2021-2031 (USD Million)
Table 13.72 HER2 Targeting Therapies Market for Gastric Cancer, 2021-2031 (USD Million)
Table 13.73 HER2 Targeting Therapies Market for Head and Neck Cancer, 2021-2031 (USD Million)
Table 13.74 HER2 Targeting Therapies Market for Lung Cancer, 2021-2031 (USD Million)
Table 13.75 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Type of Molecule (USD Million)
Table 13.76 HER2 Targeting Therapies Market for Biologics, 2021-2031 (USD Million)
Table 13.77 HER2 Targeting Therapies Market for Small Molecules, 2021-2031 (USD Million)
Table 13.78 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Type of Therapy (USD Million)
Table 13.79 HER2 Targeting Therapies Market for Monotherapy, 2021-2031 (USD Million)
Table 13.80 HER2 Targeting Therapies Market for Combination Therapy, 2021-2031 (USD Million)
Table 13.81 HER2 Targeting Therapies Market for Both, 2021-2031 (USD Million)
Table 13.82 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Route of Administration (USD Million)
Table 13.83 HER2 Targeting Therapies Market for Intravenous Therapies, 2021-2031 (USD Million)
Table 13.84 HER2 Targeting Therapies Market for Oral Therapies, 2021-2031 (USD Million)
Table 13.85 HER2 Targeting Biosimilars: Distribution by Parent Drug
Table 13.86 HER2 Targeting Biosimilars: Distribution by Phase of Development of Biosimilar
Table 13.87 HER2 Targeting Biosimilars: Distribution by Target Disease Indication
Table 13.88 HER2 Targeting Biosimilar Developers: Distribution by Year of Establishment
Table 13.89 HER2 Targeting Biosimilar Developers: Distribution by Geographical Location
Table 13.90 HER2 Targeting Biosimilar Developers: Distribution by Company Size and Geographical Location
Table 13.91 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Commercial Availability of the Test
Table 13.92 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Assay Technique Used
Table 13.93 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Corresponding Drug Candidate
Table 13.94 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Target Disease Indication
Table 13.95 Companion Diagnostics for HER2 Targeting Therapies: Distribution of Developers by Year of Establishment
Table 13.96 Companion Diagnostics for HER2 Targeting Therapies: Distribution of Developers by Company Size
Table 13.97 Companion Diagnostics for HER2 Targeting Therapies: Distribution of Developers by Geographical Location

 

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. Abbott
  2. AbbVie
  3. Acepodia
  4. AdaptVac
  5. Advaxis
  6. Affimed
  7. Agilent Technologies
  8. Aleta Biotherapeutics
  9. Alphamab Oncology
  10. AlphaVax
  11. Alpine Immune Sciences
  12. Alteogen
  13. Ambrx
  14. Amgen
  15. Amunix
  16. Anhui Anke Biotechnology
  17. Apotex
  18. Artiva Biotherapeutics
  19. AryoGen Pharmed
  20. AstraZeneca
  21. Aurora Biopharma
  22. Barbara Ann Karmanos Cancer Institute
  23. Bavarian Nordic
  24. Bayer
  25. Baylor College of Medicine
  26. BeiGene
  27. Beijing Mabworks Biotech
  28. Bellicum Pharmaceuticals
  29. BioAtla
  30. BIOCAD
  31. Biocon
  32. Biocytogen
  33. BioGenex
  34. Bio-Thera Solutions
  35. BioXpress Therapeutics
  36. Black Diamond Therapeutics
  37. Bliss Biopharmaceutical
  38. bluebird bio
  39. Boehringer Ingelheim
  40. Bolt Biotherapeutics
  41. BrightPath Biotherapeutics
  42. Bristol-Myers Squibb
  43. Byondis (formerly Synthon Biopharmaceuticals)
  44. CARISMA Therapeutics
  45. Case Western Reserve University
  46. Catalent
  47. Celcuity
  48. Celgene
  49. Cellid
  50. Celltrion Healthcare
  51. CEVEC Pharmaceuticals
  52. CinnaGen
  53. City of Hope National Medical Center
  54. Covance
  55. CSPC Pharmaceutical
  56. Curis
  57. Daiichi Sankyo
  58. Dana-Farber Cancer Institute
  59. Denali Therapeutics
  60. Dizal Pharmaceuticals
  61. DM Bio
  62. DotBio
  63. Dr. Reddy's Laboratories
  64. Dragonfly Therapeutics
  65. Duke University
  66. EirGenix
  67. Eli Lilly
  68. Etubics
  69. Evergreen Theragnostics
  70. Exelixis
  71. ExpreS2ion Biotechnologies
  72. F1 Oncology
  73. Fochon Pharmaceuticals
  74. Fosun Pharmaceutical
  75. Foundation Medicine
  76. Fudan University
  77. Genentech
  78. GeneQuantum Healthcare
  79. Genor Biopharma
  80. GlaxoSmithKline
  81. Glenmark Pharmaceuticals
  82. Goethe University Frankfurt
  83. Guardant Health
  84. H. Lee Moffitt Cancer Center and Research Institute
  85. Hanmi Pharmaceutical
  86. Harbour BioMed
  87. Heidelberg Pharma
  88. Helixmith
  89. Henlius Biotech
  90. HLB Life Science
  91. ImmuneOnco Biopharmaceuticals
  92. Imugene
  93. Indiana University
  94. InNexus Biotechnology
  95. Innovent Biologics
  96. Intas Pharmaceuticals
  97. Jiangsu Hengrui Medicine
  98. Johns Hopkins University
  99. Johnson & Johnson
  100. Juniper Pharmaceuticals
  101. JW Therapeutics
  102. Kadmon
  103. KLUS Pharma
  104. Knight Therapeutics
  105. Laboratoires Pierre Fabre
  106. LegoChem Biosciences
  107. Leica Biosystems
  108. LEO Pharma
  109. LinXis
  110. Lonza
  111. Lupin
  112. Mabpharm
  113. MabSpace Biosciences
  114. MacroGenics
  115. Marker Therapeutics
  116. Mayo Clinic
  117. Memorial Sloan Kettering Cancer Center
  118. Merck
  119. Mersana Therapeutics
  120. Merus
  121. MilliporeSigma
  122. Molecular Partners
  123. Molecular Templates
  124. Morphotek
  125. Mustang Bio
  126. National Cancer Institute (NCI)
  127. NBE Therapeutics
  128. NeuClone
  129. Nipro
  130. Novartis Pharmaceuticals
  131. NYU Langone Health
  132. Ohio State University
  133. OncoQR
  134. ORIC Pharmaceuticals
  135. OS Therapies (OST)
  136. Palleon Pharmaceuticals
  137. Parker Institute for Cancer Immunotherapy
  138. Pfizer
  139. Phio Pharmaceuticals
  140. Pieris Pharmaceuticals
  141. Precirix
  142. Prescient Therapeutics
  143. Prestige BioPharma
  144. Puma Biotechnology
  145. PX'Therapeutics
  146. QIAGEN
  147. RemeGen
  148. Roche
  149. Samsung Bioepis
  150. San Antonio Military Medical Center (SAMMC)
  151. Sanofi
  152. Seattle Genetics
  153. Second Affiliated Hospital of Guangzhou Medical University
  154. Shanghai Henlius Biotech
  155. Shanghai Miracogen
  156. Shanghai PerHum Therapeutics
  157. Shanghai Pharmaceuticals
  158. Shenzhen Geno-immune Medical Institute
  159. Shinshu University 
  160. Silverback Therapeutics
  161. Sinobioway
  162. Spectrum Pharmaceuticals
  163. Sun Yat-sen University
  164. Synaffix
  165. Taiho Oncology
  166. Takeda
  167. Tanvex BioPharma
  168. TC BioPharm
  169. Technical University of Munich
  170. Tessa Therapeutics
  171. Tevogen Bio
  172. Thermo Fisher Scientific
  173. Trinity College London
  174. Triumvira Immunologics
  175. UBiome
  176. United BioPharma
  177. University Hospital Brussels
  178. University of California
  179. University of Minnesota
  180. University of North Carolina
  181. University of Pennsylvania
  182. University of Texas
  183. University of Toronto 
  184. University of Washington
  185. UWELL Biopharma
  186. Vineti
  187. VIVEbiotech
  188. Voronoi 
  189. Xyphos Biosciences
  190. YZY Biopharma
  191. Zion Pharma
  192. Zymeworks

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com